The citrate transporter SLC13A5 as a therapeutic target for kidney disease: evidence from Mendelian randomization to inform drug development

The citrate transporter SLC13A5 as a therapeutic target for kidney disease: evidence from Mendelian randomization to inform drug development

Abstract Background Solute carrier family 13 member 5 (SLC13A5) is a Na+-coupled citrate co-transporter that mediates entry of extracellular citrate into the cytosol. SLC13A5 inhibition has been proposed as a target for reducing progression of kidney disease. The aim of this study was to leverage th...

Full description

Bibliographic Details
Main Authors: Dipender Gill, Loukas Zagkos, Rubinder Gill, Thomas Benzing, Jens Jordan, Andreas L. Birkenfeld, Stephen Burgess, Grit Zahn
Format: Article
Language:English
Published: BMC 2023-12-01
Series:BMC Medicine
Subjects:
SLC13A5
Citrate
Kidney
Renal function
Mendelian randomization
Drug development
Online Access:https://doi.org/10.1186/s12916-023-03227-5

Internet

https://doi.org/10.1186/s12916-023-03227-5

Similar Items